Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 3/20 | 0.51 |
| ▸ | ERAP2 | Q6P179 | 4/20 | 0.51 |
| ▸ | ERAP1 | Q9NZ08 | 3/20 | 0.51 |
| ▸ | IL1RN | P18510 | 3/20 | 0.51 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.50 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.49 |
| ▸ | MMP3 | P08254 | 1/20 | 0.49 |
| ▸ | LNPEP | Q9UIQ6 | 3/20 | 0.48 |
| ▸ | NPY1R | P25929 | 1/20 | 0.48 |
| ▸ | NPY4R | P50391 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17452277 | 0.93 | OPRK1 (0.52) | ERAP2ERAP1LNPEP | |
| SCHEMBL85021 | 0.92 | ALDH1A1 (0.57) | ERAP2ERAP1IL1RNBIRC2CAPN1 | |
| SCHEMBL18257509 | 0.92 | ALDH1A1 (0.57) | ERAP2ERAP1IL1RNBIRC2CAPN1 | |
| Hydrochloric Acid SCHEMBL17894107 | 0.91 | ERAP2 (0.56) | ERAP2ERAP1IL1RNBIRC2CAPN1 | |
| Hydrochloric Acid SCHEMBL18171940 | 0.91 | ERAP2 (0.56) | ERAP2ERAP1IL1RNBIRC2CAPN1 | |
| Hydrochloric Acid SCHEMBL18171932 | 0.91 | ERAP2 (0.56) | ERAP2ERAP1IL1RNBIRC2CAPN1 | |
| Hydrochloric Acid SCHEMBL17894106 | 0.91 | ERAP2 (0.56) | ERAP2ERAP1IL1RNBIRC2CAPN1 | |
| SCHEMBL2633272 | 0.86 | CPA1 (0.56) | CTSLBIRC2CAPN1MMP3 | |
| SCHEMBL2735611 | 0.85 | PSMB5 (0.49) | CTSLERAP2ERAP1IL1RNBIRC2 | |
| SCHEMBL22472895 | 0.84 | LNPEP (0.53) | ERAP2ERAP1LNPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120101026-A1 | Compounds For Enzyme Inhibition | ONYX THERAPEUTICS, INC. (US) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101026-A1 | Compounds For Enzyme Inhibition | ANPEP, DNPEP, CPN1 | CTSL 187/4885ERAP2 114/4885ERAP1 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.